747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5

Abstract

Sustained weight loss of ≥5% is highly beneficial in T2D. Here we assess the time spent with weight loss ≥5% in participants with T2D randomized to the GIP/GLP-1 receptor agonist tirzepatide (TZP) vs comparators in SURPASS 1-5. Participants were randomized to TZP (5, 10, or 15 mg) or comparator (placebo in SURPASS 1 and 5, semaglutide (SEMA) 1 mg in SURPASS 2, insulin degludec in SURPASS 3, and insulin glargine in SURPASS 4) with primary treatment durations of 40 or 52 weeks (wks). Continuous time spent with weight loss ≥5% was descriptively analyzed in all participants on treatment without rescue medication, with missing data imputed in this post-hoc analysis. In SURPASS 1-5, 54-88% of T2D participants randomized to all doses of TZP achieved body weight loss of ≥5%. TZP-treated participants experienced longer time with weight loss ≥5% than those randomized to comparators (Table 1). TZP dose-dependently increased time spent with weight loss ≥5% with the greatest durations observed in the 15 mg group (median: 24 and 40 wks in studies of 40 and 52 wks duration, respectively). Whereas, in the SURPASS 2 trial, those randomized to SEMA 1 mg spent a median of 10 weeks with weight loss ≥5%. In conclusion, TZP led to a longer continuous time spent with weight loss ≥5% compared with placebo, SEMA 1 mg, and basal insulins in participants with T2D. Disclosure W.Garvey: Advisory Panel; Boehringer-Ingelheim, Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Fractyl Health, Inc., Inogen, Research Support; Novo Nordisk, Eli Lilly and Company, Epitomee, Pfizer Inc., Neurovalens. R.L.Batterham: Advisory Panel; Novo Nordisk, GlaxoSmithKline plc., Gila Therapeutics Ltd, Pfizer Inc., Consultant; Eli Lilly and Company, Novo Nordisk, Epitomee, Speaker's Bureau; Eli Lilly and Company, Novo Nordisk, GlaxoSmithKline plc. J.Rosenstock: Advisory Panel; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Novo Nordisk, Oramed Pharmaceuticals, Sanofi, Zealand Pharma A/S, Intarcia Therapeutics, Inc., Hanmi Pharm. Co., Ltd., Research Support; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis, Novo Nordisk, Pfizer Inc., Sanofi, Intarcia Therapeutics, Inc. M.Liu: Consultant; Eli Lilly and Company. V.Thieu: None. J.Daly: Employee; Eli Lilly and Company. B.Bergman: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. Funding Eli Lilly and Company